173 related articles for article (PubMed ID: 22806876)
1. Dual inhibition of canonical and noncanonical NF-κB pathways demonstrates significant antitumor activities in multiple myeloma.
Fabre C; Mimura N; Bobb K; Kong SY; Gorgun G; Cirstea D; Hu Y; Minami J; Ohguchi H; Zhang J; Meshulam J; Carrasco RD; Tai YT; Richardson PG; Hideshima T; Anderson KC
Clin Cancer Res; 2012 Sep; 18(17):4669-81. PubMed ID: 22806876
[TBL] [Abstract][Full Text] [Related]
2. Calcium channel blocker verapamil enhances endoplasmic reticulum stress and cell death induced by proteasome inhibition in myeloma cells.
Meister S; Frey B; Lang VR; Gaipl US; Schett G; Schlötzer-Schrehardt U; Voll RE
Neoplasia; 2010 Jul; 12(7):550-61. PubMed ID: 20651984
[TBL] [Abstract][Full Text] [Related]
3. Clinical benefit of ixazomib plus lenalidomide-dexamethasone in myeloma patients with non-canonical NF-κB pathway activation.
Dash AB; Zhang J; Shen L; Li B; Berg D; Lin J; Avet-Loiseau H; Bahlis NJ; Moreau P; Richardson PG; Di Bacco A
Eur J Haematol; 2020 Sep; 105(3):274-285. PubMed ID: 32350909
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms underlying synergism between circularized tumor necrosis factor-related apoptosis inducing ligand and bortezomib in bortezomib-sensitive or -resistant myeloma cells.
Leng Y; Hu X; Li L; Nkwocha J; Satta T; Sharma K; Kmeiciak M; Zhou H; Zhang Z; Zhou L; Chen W; Grant S
Hematol Oncol; 2022 Dec; 40(5):999-1008. PubMed ID: 35789025
[TBL] [Abstract][Full Text] [Related]
5. Destabilizing NEK2 overcomes resistance to proteasome inhibition in multiple myeloma.
Franqui-Machin R; Hao M; Bai H; Gu Z; Zhan X; Habelhah H; Jethava Y; Qiu L; Frech I; Tricot G; Zhan F
J Clin Invest; 2018 Jul; 128(7):2877-2893. PubMed ID: 29863498
[TBL] [Abstract][Full Text] [Related]
6. A novel 2-iminobenzimidazole compound, XYA1353, displays in vitro and in vivo anti-myeloma activity via targeting NF-κB signaling.
Gao J; Zhou J; Zhang M; Zhang Y; Zeng Y; Li S; Xu K; Yao R
Mol Cell Biochem; 2024 Apr; 479(4):843-857. PubMed ID: 37204666
[TBL] [Abstract][Full Text] [Related]
7. Aberrant non-canonical NF-κB signalling reprograms the epigenome landscape to drive oncogenic transcriptomes in multiple myeloma.
Ang DA; Carter JM; Deka K; Tan JHL; Zhou J; Chen Q; Chng WJ; Harmston N; Li Y
Nat Commun; 2024 Mar; 15(1):2513. PubMed ID: 38514625
[TBL] [Abstract][Full Text] [Related]
8. Ribosomal protein S3 mediates drug resistance of proteasome inhibitor: potential therapeutic application in multiple myeloma.
Chen G; Gao X; Jia X; Wang Y; Xu L; Yu D; Chang S; Deng H; Hu K; Wang G; Li B; Xu Z; Lu Y; Wang H; Zhang T; Song D; Yang G; Wu X; Zhu H; Zhu W; Shi J
Haematologica; 2024 Apr; 109(4):1206-1219. PubMed ID: 37767568
[TBL] [Abstract][Full Text] [Related]
9. The ubiquitin-proteasome system as a molecular target in solid tumors: an update on bortezomib.
Milano A; Perri F; Caponigro F
Onco Targets Ther; 2009 Feb; 2():171-8. PubMed ID: 20616904
[TBL] [Abstract][Full Text] [Related]
10. Future of Personalized Therapy Targeting Aberrant Signaling Pathways in Multiple Myeloma.
Anwer F; Gee KM; Iftikhar A; Baig M; Russ AD; Saeed S; Zar MA; Razzaq F; Carew J; Nawrocki S; Al-Kateb H; Cavalcante Parr NN; McBride A; Valent J; Samaras C
Clin Lymphoma Myeloma Leuk; 2019 Jul; 19(7):397-405. PubMed ID: 31036508
[TBL] [Abstract][Full Text] [Related]
11. A novel chordoma xenograft allows in vivo drug testing and reveals the importance of NF-κB signaling in chordoma biology.
Trucco MM; Awad O; Wilky BA; Goldstein SD; Huang R; Walker RL; Shah P; Katuri V; Gul N; Zhu YJ; McCarthy EF; Paz-Priel I; Meltzer PS; Austin CP; Xia M; Loeb DM
PLoS One; 2013; 8(11):e79950. PubMed ID: 24223206
[TBL] [Abstract][Full Text] [Related]
12. A Synthetic Loop Replacement Peptide That Blocks Canonical NF-κB Signaling.
Bruno PA; Morriss-Andrews A; Henderson AR; Brooks CL; Mapp AK
Angew Chem Int Ed Engl; 2016 Nov; 55(48):14997-15001. PubMed ID: 27791341
[TBL] [Abstract][Full Text] [Related]
13. Not just for lymphoid cells: The role of the noncanonical NF-κB signaling pathway in early and late myelopoiesis with a focus on hypereosinophilic disorders.
Trusiano B; Zimmerman KL; Morrison HA; Allen IC
J Leukoc Biol; 2024 Apr; ():. PubMed ID: 38682253
[TBL] [Abstract][Full Text] [Related]
14. Scutellarin circumvents chemoresistance, promotes apoptosis, and represses tumor growth by HDAC/miR-34a-mediated down-modulation of Akt/mTOR and NF-κB-orchestrated signaling pathways in multiple myeloma.
Li L; Zheng Y; Zhang W; Hou L; Gao Y
Int J Clin Exp Pathol; 2020; 13(2):212-219. PubMed ID: 32211101
[TBL] [Abstract][Full Text] [Related]
15. SMAD1 as a biomarker and potential therapeutic target in drug-resistant multiple myeloma.
Wu J; Zhang M; Faruq O; Zacksenhaus E; Chen W; Liu A; Chang H
Biomark Res; 2021 Jun; 9(1):48. PubMed ID: 34134766
[TBL] [Abstract][Full Text] [Related]
16. Multiple Myeloma Inhibitory Activity of Plant Natural Products.
Jöhrer K; Ҫiҫek SS
Cancers (Basel); 2021 May; 13(11):. PubMed ID: 34072312
[TBL] [Abstract][Full Text] [Related]
17. Positioning NK-kappaB in multiple myeloma.
Klein B
Blood; 2010 Apr; 115(17):3422-4. PubMed ID: 20430962
[No Abstract] [Full Text] [Related]
18. NF-κB-activating complex engaged in response to EGFR oncogene inhibition drives tumor cell survival and residual disease in lung cancer.
Blakely CM; Pazarentzos E; Olivas V; Asthana S; Yan JJ; Tan I; Hrustanovic G; Chan E; Lin L; Neel DS; Newton W; Bobb KL; Fouts TR; Meshulam J; Gubens MA; Jablons DM; Johnson JR; Bandyopadhyay S; Krogan NJ; Bivona TG
Cell Rep; 2015 Apr; 11(1):98-110. PubMed ID: 25843712
[TBL] [Abstract][Full Text] [Related]
19. NF-κB, inflammation, immunity and cancer: coming of age.
Taniguchi K; Karin M
Nat Rev Immunol; 2018 May; 18(5):309-324. PubMed ID: 29379212
[TBL] [Abstract][Full Text] [Related]
20. Relevance of SIRT1-NF-κB Axis as Therapeutic Target to Ameliorate Inflammation in Liver Disease.
de Gregorio E; Colell A; Morales A; Marí M
Int J Mol Sci; 2020 May; 21(11):. PubMed ID: 32485811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
